Metacrine, Inc (MTCR)

Etorro trading 970x250

About Metacrine, Inc

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Address: 3985 Sorrento Valley Boulevard, San Diego, CA, United States, 92121

Metacrine, Inc News and around…

Latest news about Metacrine, Inc (MTCR) common stock and company :

Overview Of Value Stocks In The Healthcare Sector
29 Nov, 2021 FinancialContent

What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. ...

Metacrine Reports Third-Quarter 2021 Results
11 Nov, 2021 Yahoo! Finance

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today reported its third-quarter 2021 financial results. “Our recent monotherapy and combination trial results demonstrate the strong therapeutic profile of our FXR program in non-alcoholic steatohepatitis (NASH), while also highlighting the potential of these agents as an important part o

Metacrine Posts Data From MET409 Combination Trial In Diabetes, NASH Patients
02 Nov, 2021 FinancialContent

Metacrine Inc(NASDAQ: MTCR)reported topline resultsfrom its Phase 2a trial of MET409 in combination withEli ...

Metacrine Reports Topline Results for MET409 Phase 2a Combination Trial In Patients with Type 2 Diabetes and NASH
02 Nov, 2021 Yahoo! Finance

- Validates therapeutic benefit of combination approaches for a large segment of NASH patients- Demonstrates additive efficacy results and favorable tolerability profile SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today reported topline results from its Phase 2a trial evaluating MET409, a farnesoid X receptor (FXR) agonist, in combi

How The Future Looks For Last Week's Biggest Losers: Vinco Ventures, Atea Pharmaceuticals And More
25 Oct, 2021 FinancialContent

Last week, the five biggest stock market losers declined between about 75% and 37%. Below is a look at each stock and what they may have ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
25 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader! We're kicking off another busy week of trading with lists of the biggest pre-market stock movers for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

55 Biggest Movers From Friday
25 Oct, 2021 FinancialContent

Gainers Phunware, Inc. (NASDAQ: PHUN) shares jumped 471.2% to close at $8.74 on Friday. Phunware shares jumped over 45% on ...

Mid-Afternoon Market Update: Nasdaq Down 70 Points; Ocular Therapeutix Shares Drop
22 Oct, 2021 FinancialContent

Toward the end of trading Friday, the Dow traded up 0.23% to 35,685.44 while the NASDAQ fell 0.46% to 15,145.51. The S&P also fell, ...

Mid-Day Market Update: Snap Drops After Q3 Results; Creatd Shares Jump
22 Oct, 2021 FinancialContent

Midway through trading Friday, the Dow traded up 0.25% to 35,690.68 while the NASDAQ fell 0.46% to 15,145.78. The S&P also rose, ...

35 Stocks Moving In Friday's Mid-Day Session
22 Oct, 2021 FinancialContent

Gainers Phunware, Inc. (NASDAQ: PHUN) rose 1099% to $18.35. Phunware shares jumped over 45% on Thursday, possibly in sympathy with ...

26 Stocks Moving in Friday's Pre-Market Session
22 Oct, 2021 FinancialContent

Gainers Phunware, Inc. (NASDAQ: PHUN) rose 300% to $6.10 in pre-market trading. Phunware shares jumped over 45% on Thursday, ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
22 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Happy Friday, trader! The week's almost done and we're starting off the final day of it with a look at the biggest pre-market stock movers! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Metacrine Reports Interim Results for MET642 Phase 2a Trial in Patients with NASH and Announces a Strategic Re-Prioritization of Its Clinical Development Programs
21 Oct, 2021 Yahoo! Finance

SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today reported interim results from a Phase 2a clinical trial evaluating the efficacy and safety of MET642, a farnesoid X receptor (FXR) agonist, in approximately 60 non-alcoholic steatohepatitis (NASH) patients after 16 weeks of treatment. The Company also announced it is prioritizing its

Implied VTI Analyst Target Price: $255
08 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Total Stock Market ETF (VTI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $255.38 per unit.

48 Biggest Movers From Friday
27 Sep, 2021 FinancialContent

Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares climbed 58% to close at $5.45 on Friday. Clearwater Analytics Holdings, ...

Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash
09 Sep, 2021 FinancialContent
Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021
08 Sep, 2021 FinancialContent
Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference
07 Sep, 2021 FinancialContent
Implied IWC Analyst Target Price: $202
02 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $202.17 per unit.

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results
12 Aug, 2021 FinancialContent
Metacrine to Present at 2021 Canaccord Genuity Growth Conference
09 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
29 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
28 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Tuesday
27 Jul, 2021 FinancialContent

During Tuesday's morning session, 216 companies made new 52-week lows. Noteworthy Points: Alibaba Group ...

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
27 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
20 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Metacrine to Present New Preclinical Data in Inflammatory Bowel Disease (IBD) at European Crohn’s and Colitis Organisation (ECCO) 2021 Virtual Congress 
06 Jul, 2021 FinancialContent

Metacrine, Inc (MTCR) is a NASDAQ Common Stock listed in , ,

970x250